RegenSphere is pioneering a new era in chronic and complex wound care through cutting-edge bio-regenerative medicine. Specialising in autologous (patient-derived) treatments, our service combines Platelet-Rich Plasma (PRP), adipose-derived stromal vascular cells, and bone marrow-based regenerative therapies to stimulate natural healing, reduce inflammation, and restore healthy tissue function in hard-to-heal wounds.
Chronic wounds such as leg ulcers, pressure sores, and diabetic foot wounds are becoming increasingly prevalent particularly among older adults and those with fragile skin. These wounds not only cause immense pain and reduce quality of life, but they also significantly increase the risk of infection, hospitalisation, and amputation.
What makes RegenSphere truly different is our mobile, peripatetic model. We bring care directly to patients whether at home, in residential care settings, or through outpatient clinics. This model reduces the need for hospital visits, accelerates recovery, and supports more timely, integrated care. We also bridge a critical gap between GPs, specialist clinicians, and hospitals, offering a valuable extension to both private and public healthcare pathways.
A cornerstone of our innovation is the Biodynamic Haematocele Wound Care Treatment – a proprietary technique developed by RegenSphere through rigorous clinical research. This advanced methodology uses the body’s own haemostatic and regenerative mechanisms to accelerate wound closure, improve tissue regeneration, and reduce healing time in even the most complex chronic wounds.
RegenSphere proudly supports referrals from Integrated Care Boards (ICBs), care homes, private hospitals, and community services, ensuring that more patients can access next-generation therapies when and where they need them most.
The economic burden is equally severe, with the NHS spending over £1 billion annually on diabetic foot ulcers alone, and more than 11,000 lower limb amputations carried out each year due to diabetes-related complications.
RegenSphere offers a powerful solution. Our approach blends MHRA-approved autologous regenerative therapies with more traditional wound management tools, including negative pressure wound therapy and advanced dressings.
Treatments are delivered by a team of Tissue Viability Nurses (TVNs), wound care specialists, and trained biotech professionals, all under the guidance of experienced clinicians.
Regenerative medicine is one of the most exciting and rapidly advancing fields in modern healthcare. Bio-regenerative therapies – especially those using cellular and molecular components, are transforming how we approach healing, offering the potential to harness the body’s own repair mechanisms.
Two of the most promising therapies leading this revolution are autologous Platelet-Rich Plasma Therapies (aPRPT) and Autologous Fat Cellular Therapies. Platelets are the regenerative ‘powerhouses’ that drive cell activity, while fat-derived stem cells act as foundational building blocks. Together, they stimulate healing by releasing growth factors, settling inflammation and triggering regenerative signaling.
To address the challenges of accessibility and clinical adoption, Regensphere developed a proprietary service model that brings complex cellular therapies directly to point-of-care. Our biologically active autologous therapies are designed to support clinicians in delivering effective regenerative outcomes—without the barriers of technical complexity or large capital investment.
Regensphere began as a specialist provider of innovative autologous cellular therapies in complex wound care, aesthetics, and reconstructive surgery.
We understood early on that innovation alone wasn’t enough; successful clinical adoption would require UK-based clinical studies to validate safety and efficacy, expert delivery support at point-of-care, and a streamlined mechanism for integrating biodynamic therapies into clinical settings.
We then expanded into advanced wound care and funded major studies, including the Queen Elizabeth Hospital, Birmingham (MoD Study), focused on trauma and slow-healing wounds, with one case achieving 79% wound closure in 13 days.
Regensphere provides an integrated, end-to-end clinical support service for autologous PRP and fat-based bioactive therapies.
Our operational model is designed to accelerate the adoption of advanced regenerative technologies, minimise clinical risk, and enable seamless, case-by-case access for clinicians.
We focus on tissue regeneration in complex wound care and aesthetics, translating biotech into real-world clinical results.
Our leadership team combines decades of experience in regenerative medicine, research, healthcare delivery, and strategic development. We specialise in clinical execution of regenerative therapies, scientific research and validation, operational delivery models in healthcare, and strategic finance.
With a career spanning more than four decades in healthcare, Dr. Aamer Khan has built extensive expertise across both the NHS and private sector, specialising in integrative medicine, General Practice, and advanced cosmetic, reconstructive, and regenerative treatments.
His long-standing interest in cellular biology and regenerative medicine is backed by in-depth study and practical experience. As CEO of RegenSphere, he combines clinical excellence with a humanitarian vision for sustainable health, guiding the organisation’s pioneering approach to patient care.
With over 30 years in healthcare across the NHS, Johnson & Johnson, United Healthcare, and biotech ventures, Janet holds an MBA from De Montfort University.
Janet is passionate about the introduction of innovative technologies and developing the skills and processes that will transform healthcare delivery and provide patients with greater choice and produce better healthcare outcomes.
She combines clinical insight with business acumen to lead RegenSphere’s unique service model as Operations Director.
Be part of a movement transforming wound care and regenerative medicine.
RegenSphere leads the advancement of regenerative cellular therapies. From complex wound treatment to tissue regeneration in aesthetic medicine and surgery, the mission is to bridge cutting-edge science with real-world patient outcomes.
Forward-thinking clinicians, providers, and regenerative medicine specialists are invited to join this growing community. As a Certified RegenSphere Clinician and Technician partner, you’ll deliver scientifically proven, minimally invasive therapies that accelerate healing and restore function—directly at the point of care.
The programme is designed for professionals who are committed to learning, excellence, and ethical care. Success depends on:
We aim to make regenerative medicine accessible, effective, and scalable. With our proven therapies, delivery model, and expert team, we’re positioned as a market leader in specialist autologous biodynamic therapies. We’re not just innovating—we’re transforming lives.
“RegenSphere represents a step-change in how we approach wound healing in the UK. This is not just about treatment, it’s about transformation. By bringing regenerative medicine into community settings, we’re not only helping patients to heal faster and more effectively, but also reducing the immense strain chronic wounds place on the NHS. We’re proud to offer a service that supports both clinical excellence and systemic sustainability.”
Contact us today for more information or to arrange an assessment.
RegenSphere Ltd. Registered in England and Wales. Company Registration Number: 16379989 Company Registered Office Address: Hale House Unit 5, 296a Green Lanes, Palmers Green, London, United Kingdom, N13 5TW
